-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Relay Therapeutics, Raises Price Target to $15

Benzinga·02/27/2026 17:50:54
Listen to the news
Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $13 to $15.